Louisiana State Employees Retirement System Buys New Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Louisiana State Employees Retirement System bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 19,200 shares of the medical equipment provider’s stock, valued at approximately $1,190,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Tucker Asset Management LLC increased its stake in Lantheus by 239.0% in the 3rd quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 282 shares during the last quarter. First Horizon Advisors Inc. increased its stake in Lantheus by 97.0% in the 3rd quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 225 shares during the last quarter. Covestor Ltd increased its stake in Lantheus by 62.7% in the 3rd quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 203 shares during the last quarter. Parkside Financial Bank & Trust increased its stake in Lantheus by 36.6% in the 3rd quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock worth $40,000 after acquiring an additional 156 shares during the last quarter. Finally, NBC Securities Inc. bought a new stake in Lantheus in the 3rd quarter worth approximately $46,000. Institutional investors own 99.06% of the company’s stock.

Insider Activity at Lantheus

In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was bought at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the acquisition, the insider now directly owns 116,773,394 shares in the company, valued at $110,934,724.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the sale, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the stock in a transaction on Wednesday, March 6th. The stock was purchased at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the acquisition, the insider now directly owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The disclosure for this purchase can be found here. Insiders sold a total of 94,545 shares of company stock worth $6,169,936 in the last quarter. 2.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. JMP Securities reaffirmed a “market outperform” rating and issued a $100.00 price objective on shares of Lantheus in a research note on Friday, February 23rd. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. Truist Financial reissued a “buy” rating and set a $82.00 target price (up previously from $80.00) on shares of Lantheus in a research report on Monday, February 26th. Finally, B. Riley boosted their target price on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research report on Thursday, April 18th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $104.71.

Lantheus Price Performance

LNTH opened at $63.07 on Tuesday. The business has a fifty day moving average of $60.94 and a 200 day moving average of $62.78. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $100.85. The company has a quick ratio of 5.45, a current ratio of 5.80 and a debt-to-equity ratio of 0.69. The stock has a market cap of $4.32 billion, a P/E ratio of 13.59 and a beta of 0.54.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.33 by $0.26. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. The company had revenue of $354.00 million during the quarter, compared to analysts’ expectations of $350.44 million. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 5.72 EPS for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.